[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355341-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-355341-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","galnt1-emerges-as-a-potential-therapeutic-target-in-breast-cancer","GALNT1 emerges as a potential therapeutic target in breast cancer","","GALNT1 is examined as a key enzyme in O-GalNAc glycosylation whose role in the tumor microenvironment has remained insufficiently defined in breast cancer. The study integrates public datasets (TCGA, GEO, CPTAC) with single-cell transcriptomic data to map expression across cancers and at single-cell resolution. Using qRT-PCR, Western blot, and immunofluorescence, it validates GALNT1 localization in breast cancer. Functional assays test effects on proliferation, migration, O-glycosylation, and bortezomib sensitivity, revealing immune microenvironment remodeling linked to drug resistance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/galnt1-emerges-as-a-potential-therapeutic-target-in-breast-cancer/355341/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/galnt1-emerges-as-a-potential-therapeutic-target-in-breast-cancer/355341.png","ImageObject",300,407,{"name":42,"@type":43},"\tJames","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is GALNT1 and why is it studied in breast cancer?","Question",{"text":63,"@type":64},"GALNT1 is an enzyme mediating O-GalNAc glycosylation. The study investigates its expression pattern, molecular mechanisms, and clinical relevance, especially within the tumor microenvironment.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was GALNT1 expression analyzed in the study?",{"text":68,"@type":64},"Public datasets (TCGA, GEO, CPTAC) were integrated with single-cell transcriptomic data to assess GALNT1 expression across cancer types and at single-cell resolution.",{"name":70,"@type":61,"acceptedAnswer":71},"What functional role does GALNT1 play, and how does it relate to drug resistance?",{"text":72,"@type":64},"GALNT1 upregulation promotes breast cancer cell proliferation, migration, and O-glycosylation. O-glycosylation mediated by GALNT1 is associated with resistance to bortezomib.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},355341,1790190343,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":26,"preview_urls":146},2336474466412,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Journal of Cancer Research and Clinical Oncology (2026) 152:74  \n[https://doi.org/10.1007/s00432-026-06448-2](https://doi.org/10.1007/s00432-026-06448-2)  \nRESEARCH  \nGALNT1 emerges as a potential therapeutic target in breast cancer  \nJiafu Li1,2 · Pei Zhong1,2 · Xizhuang Li1,2 · Rongzhi Huang1,2 · Zexu Zhan1,2 · Jiehua Li1 · Min Mao3  \nReceived: 12 November 2025 / Accepted: 22 February 2026 © The Author(s) 2026  \nAbstract  \nPurpose GALNT1, a key enzyme mediating O-GalNAc glycosylation, has not been fully characterized in the tumor microenvironment. This study aimed to investigate its expression pattern, molecular mechanisms, and clinical relevance in breast cancer.  \nMethods Public datasets (TCGA, GEO, CPTAC) and single-cell transcriptomic data were integrated to analyze GALNT1 expression across cancer types and at the single-cell resolution. The expression and subcellular localization of GALNT1 in breast cancer were verified using qRT-PCR, Western blot, and immunofluorescence staining. Functional assays were conducted to assess its effects on cell proliferation, migration, and O-glycosylation, while CCK-8 assays were used to evaluate sensitivity to bortezomib.  \nResults GALNT1 was significantly upregulated in primary breast cancer as well as multiple other malignancies. In vitro experiments demonstrated that GALNT1 promoted breast cancer cell proliferation, migration, and O-glycosylation. Immunofluorescence staining revealed widespread GALNT1 expression in tumor epithelial cells and cancer-associated fibroblasts (CAFs), with colocalization to the Tn antigen. Notably, GALNT1-mediated O-glycosylation was associated with resistance to bortezomib. High GALNT1 expression correlated with increased infiltration of CAFs and M2 macrophages, and reduced CD8⁺ T cell infiltration. Single-cell transcriptomic analysis further confirmed CAF-specific enrichment and elevated epithelial-mesenchymal transition (EMT) scores.  \nConclusions GALNT1 is highly expressed in breast cancer, where it promotes tumor progression, bortezomib resistance through O-glycosylation, and immune microenvironment remodeling. The data imply that GALNT1 could represent a novel therapeutic candidate in breast cancer.  \nKeywords Breast cancer · GALNT1 · Drug resistance · Single-cell transcriptomics · Tumor microenvironment  \nJiafu Li and Pei Zhong have contributed equally to this work and should be considered as co-first authors.  \n􀀍 Jiehua Li[lijiehua01@sina.com](lijiehua01@sina.com)  \n􀀍 Min Mao [min15289679719@163.com](min15289679719@163.com)  \n1 Department of Gastrointestinal and Gland Surgery, The First Affiliated Hospital of Guangxi Medical University, 6 Shuang-Yong Road, Nanning 530021, The Guangxi Zhuang Autonomous Region, China  \n2 Guangxi Key Laboratory of Enhanced Recovery After Surgery for Gastrointestinal Cancer, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China  \n3 Department of Thyroid and Breast Surgery, The First People’s Hospital of Qinzhou, Qinzhou 535000, Guangxi, China  \nAbbreviations  \nBC Breast cancer  \nTME Tumor microenvironmentscRNA Single-cell RNA sequencing CAFs Cancer-associated fibroblasts EMT Epithelial–mesenchymal transition ECM Extracellular matrix  \nER Endoplasmic Reticulum  \nIntroduction  \nBreast cancer (BC) represents the most prevalent cancer type affecting women worldwide and remains a major clinical challenge, largely due to its pronounced heterogeneity and therapeutic resistance (Nolan et al. 2023) . Emerging evidence suggests that these malignant features are not  \n1 3  \nsolely intrinsic to cancer cells but are orchestrated mainly by the tumor microenvironment (TME), a dynamic network of immune cells, stromal cells, and extracellular matrix components that interact with tumor cells to promote progression, immune evasion, and modulate treatment response (Wilson et al. 2022) .  \nIn regulating the tumor microenvironment, increasing attention has been given to abnormal post-translational modif","cbCaiiIDXMPySgK3","https://ap.wps.com/l/cbCaiiIDXMPySgK3","pdf",2444810,13,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Tumor microenvironment and therapeutic resistance\n## O-GalNAc glycosylation and GALNT1 rationale\n# Methods\n## Data acquisition","[{\"question\":\"What is GALNT1 and why is it studied in breast cancer?\",\"answer\":\"GALNT1 is an enzyme mediating O-GalNAc glycosylation. The study investigates its expression pattern, molecular mechanisms, and clinical relevance, especially within the tumor microenvironment.\"},{\"question\":\"How was GALNT1 expression analyzed in the study?\",\"answer\":\"Public datasets (TCGA, GEO, CPTAC) were integrated with single-cell transcriptomic data to assess GALNT1 expression across cancer types and at single-cell resolution.\"},{\"question\":\"What functional role does GALNT1 play, and how does it relate to drug resistance?\",\"answer\":\"GALNT1 upregulation promotes breast cancer cell proliferation, migration, and O-glycosylation. O-glycosylation mediated by GALNT1 is associated with resistance to bortezomib.\"}]","GALNT1 emerges as a potential therapeutic target in breast cancer | PDF",1790117897,33,[147,151],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/c97c5a3e33ae697d231cb305da624c49.webp",983,1306,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/0968a8d0058e4f9f22fd366b6c5f302b.webp",982,1304]